MoneyTV Interview With Donald Baillargeon
On MoneyTV with Donald Baillargeon, Halberd Corporation CEO William Hartman explained why they chose Arizona State University as their research partner.
Sep 3 2020
Sep 2 2020
Why Halberd Corporation Selected ASU And Where They Stand Among Other Universities
Jackson Center, PA, September 2, 2020 – Halberd Corporation (OTC PINK: "HALB") today revealed why they selected Arizona State University (ASU) to conduct sponsored research to develop a Covid-19 treatment. ASU is one of the fastest growing research universities in the country and ranks among the top 10 for Department of Health and Human Services ...
Aug 31 2020
Halberd Selects Arizona State University (ASU) to Develop Its Patented Covid-19 Treatment(s)
Jackson Center, PA, August 31, 2020 – Halberd Corporation (OTC PINK: "HALB") today announced the signing of a development agreement with Arizona State University (ASU) to conduct sponsored research to develop Halberd’s Covid-19 treatments. The work will focus on developing antibodies in support of Halberd’s two issued patents and three Covid-19 related provisional patent applications ...
Aug 27 2020
Halberd Corporation Selects University Research Partner
Jackson Center, PA, August 27, 2020 – Halberd Corp. (OTC PINK: "HALB") is pleased to announce the successful completion of its search for a major research university partner. The University, to be announced, is engaged to develop compounds for use in Halberd’s patented extracorporeal treatment of Covid-19. Terms of the agreement have been finalized and ...
Aug 18 2020
Halberd Corporation CEO Answers Shareholders’ Questions Regarding Covid-19 Treatment
Jackson Center, PA, August 18, 2020 – Halberd Corp. (OTC PINK: "HALB") Chairman, President & CEO of Halberd Corporation, William A. Hartman, has received a number of questions from shareholders regarding the extracorporeal process for treatment of Covid-19. Below, Mr. Hartman responds to those questions. Q: There are various extracorporeal medical procedures being researched or ...
Aug 10 2020
Halberd Corporation Adds Dr. Abdon Nanhay to Scientific Advisory Board
Furthering the Fight Against Covid-19 Internationally Jackson Center, PA, August 10, 2020 – Halberd Corp. (OTC PINK: "HALB") today confirmed the addition of Dr. Abdon Nanhay as a member of the Scientific Advisory Board. Dr. Nanhay, a Brazilian physician, has over 25 years of experience in health and biological sciences. Dr. Nanhay’s experiences include general ...
Aug 4 2020
Halberd Corporation Secures $2 Million for Covid-19 Research
Jackson Center, PA, August 4, 2020 – Halberd Corp. (OTC PINK: "HALB") announced today that they have secured non-dilutive, grant-based funding for their patent pending Covid-19 treatment(s). Newly formed Nonprofit Organization, Epidemiologic Solutions Corporation, a Louisiana, Internal Revenue Code Section 501(c)(3) application pending, has committed to provide funding of approximately $2,000,000, as required by Halberd ...
Jul 16 2020
Halberd Advances the Treatment of COVID-19 Utilizing Laser Technology
Jackson Center, PA, July 16, 2020 – Halberd Corp. (OTC PINK: "HALB") intends to use laser technology to eradicate the COVID-19 Coronavirus. This patent pending treatment introduces one or more fluorescent antibody-antigen complexing agents to bind with the target antigen(s) (i.e., Covid-19 target antigens). This will allow the virus to be seen and located, and ...
Jul 13 2020
Halberd Corp – Update July 13, 2020 – Addresses Certain Issues
Jackson Center, PA, July 13, 2020 – Halberd Corp. (OTC PINK: "HALB") today issued a statement to clarify certain items within its charter regarding allowable debt. There have been inaccurate rumors that have put the company in a negative light. One of these is that the company intends to take on convertible debt. Nothing could ...
Jul 7 2020
COVID-19 Cytokine Storm, Coronavirus’ Deadliest Stage – Halberd’s US Patent Pending Treatment Now Explained!
Jackson Center, PA, July 7, 2020 – Halberd Corp. (OTC PINK: "HALB") today explains the second of three (3) COVID -19 (Coronavirus) patent pending treatments - “Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients” - which was filed with the U.S. Patent and Trademark Office on ...